Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS G12C-mutated Solid Tumors, Lung Cancer”

22 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 22 results

Early research (Phase 1)Study completedNCT04330664
What this trial is testing

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplastic Disease
Mirati Therapeutics Inc. 86
Testing effectiveness (Phase 2)Ended earlyNCT04165031
What this trial is testing

LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Who this might be right for
Advanced Solid TumorNon-Small Cell Lung CancerColorectal Cancer
Eli Lilly and Company 5
Early research (Phase 1)Looking for participantsNCT06447662
What this trial is testing

Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Who this might be right for
Carcinoma, Pancreatic DuctalColorectal NeoplasmsCarcinoma, Non-Small-Cell Lung
Pfizer 330
Testing effectiveness (Phase 2)Study completedNCT05002270
What this trial is testing

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Who this might be right for
Advanced Solid TumorNSCLCCRC
Jacobio Pharmaceuticals Co., Ltd. 29
Early research (Phase 1)Not Yet RecruitingNCT06594874
What this trial is testing

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd. 350
Not applicableNot Yet RecruitingNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Early research (Phase 1)Ended earlyNCT05840510
What this trial is testing

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

Who this might be right for
Solid Tumor, AdultNSCLCAdvanced Cancer+2 more
Mirati Therapeutics Inc. 6
Early research (Phase 1)Looking for participantsNCT06130254
What this trial is testing

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Who this might be right for
Advanced Solid TumorNon-small Cell Lung Cancers
M.D. Anderson Cancer Center 52
Testing effectiveness (Phase 2)Looking for participantsNCT05288205
What this trial is testing

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Who this might be right for
KRAS P.G12CNon-small Cell Lung CancerColorectal Cancer+1 more
Allist Pharmaceuticals, Inc. 240
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Early research (Phase 1)Ended earlyNCT04975256
What this trial is testing

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplasm of Colon+2 more
Mirati Therapeutics Inc. 7
Early research (Phase 1)Study completedNCT04006301
What this trial is testing

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Who this might be right for
NeoplasmsAdvanced Solid TumorsNon-small Cell Lung Cancer+1 more
Janssen Research & Development, LLC 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT05358249
What this trial is testing

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung+8 more
Novartis Pharmaceuticals 74
Early research (Phase 1)Active Not RecruitingNCT04449874
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Who this might be right for
Non-Small Cell Lung CancerColorectal CancerAdvanced Solid Tumors
Genentech, Inc. 498
Testing effectiveness (Phase 2)Looking for participantsNCT06162221
What this trial is testing

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Who this might be right for
Non-Small Cell Lung Cancer, NSCLCKRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more
Revolution Medicines, Inc. 616
Testing effectiveness (Phase 2)Looking for participantsNCT04956640
What this trial is testing

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Who this might be right for
Carcinoma, Non-Small-Cell LungColorectal NeoplasmsEndometrial Neoplasms+3 more
Eli Lilly and Company 540
Early research (Phase 1)Active Not RecruitingNCT05485974
What this trial is testing

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Who this might be right for
Lung CancerNon Small Cell Lung CancerColorectal Cancer+4 more
HUYABIO International, LLC. 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 311
Early research (Phase 1)Ended earlyNCT05480865
What this trial is testing

SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Who this might be right for
Solid Tumor, AdultMetastatic Solid TumorMetastatic NSCLC+1 more
Navire Pharma Inc., a BridgeBio company 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Load More Results